Adverse Drug Events/Reactions



Medicines Information Centre | National HIV & TB Health Care Worker Hotline



Briony

Anri

Firdause



Myra

CI JU



Annoesjka

Jackie





Ewan

Mandy

*

Definitions & Terminology

Pharmacovigilance:

The science and activities relating to the detection, assessment, understanding and prevention of long term and short-term adverse effects of medicines or any other medicine-related problems.

Adverse Drug Event (ADE)

Any untoward medical occurrence in a patient (or clinical trial subject) administered a medicine that may present during treatment with that medicine, but which does not necessarily have a causal relationship with this treatment. > Any unfavourable and unintended sign, symptom or disease temporally associated with the use of a medicine, whether

considered related to the medicine or not.

Adverse Drug Reaction (ADR) | Adverse Effect (AE)

Any response to a drug (medicine) which is noxious (adverse) and unintended, and which occurs at doses normally used in man for prophylaxis, diagnosis, or treatment of disease, or for the modification of physiological function, including lack of efficacy, and can result from overdose, misuse or abuse of any drug.


Medication Error (preventable ADE/ ADR)

Any preventable event resulting from failure in the treatment process, including prescribing, dispensing, medicine preparation, administration and monitoring errors, and which has the potential to cause or lead to inappropriate medication use and harm to the patient.

ADVERSE DRUG EVENT (ADE)

No causal relationship established between drug therapy and occurrence of the event Amlodipine? Amitriptyline? Simvastatin? Enalapril? **ACCIDENT > DEATH ADVERSE DRUG REACTION (ADR)** Possible causal relationship established between time of drug exposure (amitriptyline) and occurrence of the event **Onset of suspected ADR - 10:00 PM** Drug exposure - 9:00 PM **Occurrent of ADE - 10:30 PM DROWSINESS > SLEEP** Amitriptyline **MEDICATION ERROR (ME)** Preventable ADR **Preventable ADE** 00 **AMITRIPTYLINE OVERDOSE**

ADE - ADR - ME Relationship



Many ADRs are preventable and may lead to serious health issues and even death

SOUTH AFRICA



BJCP British Journal of Clinical Pharmacology BITTISH BI

Mortality from adverse drug reactions in adult medical inpatients at four hospitals in South Africa: a cross-sectional survey

Hospital Admissions:

- 1 in 12 admissions were due to an ADR
- 45% of ADRs were preventable

Mouton JP et al. Medicine (Baltimore). 2016 May;95(19):e3437

Mortality following admissions:

- ADRs contributed to the death of 2.9% of medical admissions
- Overall mortality was 18 per 100 admissions and 16% of these deaths were ADR-related
- 43% of ADR-related deaths were preventable

Mouton JP et al. Br J Clin Pharmacol. 2015 Oct;80(4):818-26

Classification of ADRs

Type of reaction	Mnemonic	Features	Examples • Toxic effects: Digoxin toxicity; serotonin syndrome with SSRIs • Side effects: Anticholinergic effects of tricyclic antidepressants			
A: Dose-related	Augmented	 Common Related to a pharmacological action of the drug Predictable Low mortality 				
B: Non-dose-related	Bizarre	 Uncommon Not related to a pharmacological action of the drug Unpredictable High mortality 	Immunological reactions: Penicillin hypersensitivity Idiosyncratic reactions: Acute porphyria Malignant hyperthermia Pseudoallergy (eg, ampicillin rash)			
C: Dose-related and time-related	Chronic	Uncommon Related to the cumulative dose	 Hypothalamic-pituitary-adrenal axis suppression by corticosteroids 			
D: Time-related	Delayed	Uncommon Usually dose-related Occurs or becomes apparent some time after the use of the drug	 Teratogenesis (eg, vaginal adenocarcinoma with diethylstilbestrol) Carcinogenesis Tardive dyskinesia 			
E: Withdrawal	End of use	Uncommon Occurs soon after withdrawal of the drug	 Opiate withdrawal syndrome Myocardial ischaemia (β-blocker withdrawal) 			
F: Unexpected failure of therapy	Failure	Common Dose-related Often caused by drug interactions	 Inadequate dosage of an oral contraceptive, particularly when used with specific enzyme inducers 			

SSRIs=serotonin-selective reuptake inhibitors.

TYPE A, C, D, E, F are related to the pharmacological properties of the drug


TYPE B are **not** related to the pharmacological properties of the drug

Lancet 2000; 356: 1255–59

"There are known knowns. There are things we know we know. We also know there are known unknowns; that is to say, we know there are some things we do not know. But there are also unknown unknowns - the ones we don't know we don't know."

Donald Rumsfeld, 2002.

Limitations of studies during clinical development



Small number of patients (< 5000 participants enrolled)

Limited/excluded populations (age, gender, ethnicity, co-morbidities, pregnancy, breastfeeding)

□ Limited duration, short follow-up – limited/unknown safety data on long-term and rare reactions

Conditions and indications differ from those in clinical practice (off-label use)

Source: World Health Organization. 2004. WHO Policy Perspectives on Medicines - Pharmacovigilance : ensuring the safe use of medicines. World Health Organization. Available at: <u>https://apps.who.int/iris/handle/10665/68782</u>

The importance of post-marketing surveillance to identify ADRs

Preclinical Animal Experiments	Phase I Phase	II Phase III	Phase IV Post-approval	Spontaneous Reporting	
		tration			
	Development	Post Registration			
Very common	Common	Uncommon	Rare	Very rare	
≥ 10 %	1-10%	0.1 – 1 %	0.01-0.1 %	< 0.01 %	
≥ 1 in 100	1 – 10 in 100	1 – 10 in 1000	1 – 10 in 10 000	< 1 in 10 000	
Very common /	uncommon and short-term Identified in clinical trials	Limited/lacking info on long-term and rare adverse effects			
	Identified ADRs/risks Known knowns	Unidentified Known unknowns &			

Rule of 3

95% confidence in observing 1 occurrence of an event requires exposed group 3 times the size of the event's frequency

Council for International Organizations of Medical Sciences (CIOMS)

ADE Detection Methods

Spontaneous reporting

Voluntary reporting (main method used internationally by members of WHO Programme for International Drug Monitoring)

Medical record or chart review

- Systematic method for identifying ADEs
- Pros detects more ADEs vs spontaneous reporting and computerized surveillance
- Cons costly and time-consuming, ADEs are not reliably recorded in the medical record due to variable standards for documentation, liability concerns, lack of clinician awareness of the ADE, and incomplete record retrieval.
- ADE trigger tools list of clinical "clues" that an ADE may have occurred.
 - antidote medications such as naloxone for opioid-related ADEs
 - abnormal laboratory tests (i.e., renal function or transaminase elevation) that may indicate medication-related toxicity

Computerized surveillance

- Pros detects many events not captured by voluntary reporting. Useful to monitor a large patient population continuously, requires little labour hours than chart review.
- Cons limited access to automated surveillance systems.

Direct observation - most effective method to medication errors (especially administration errors) but expensive.

Reports by patients and family members - complements other approaches, but its performance in operational settings requires further study.

Spontaneous Reporting & Signal Detection

Spontaneous reporting - passive surveillance method of healthcare professionals and patients voluntarily reporting ADEs to detect signals of suspected ADRs .

	Pros	Cons					
•	Most common passive surveillance method	•	Under- or incomplete reporting (quality and quantity of data)				
•	Easy and least labour-intensive method	•	No denominator – cannot determine incidence or risk rates				
•	Covers all population and includes all medicines	•	Bias and variance in voluntary reporting:				
•	Monitoring throughout life-cycle of a medicine		 Significance - seriousness vs. severity of reactions Time since market introduction (new vs. old medicine) 				
•	Detect previously unknown/rare reactions		 Advertising/ promotional claims 				
•	Useful in identifying signals and trends		 Publicity of specific ADRs and specific drug association 				


Causality Assessment & Signal Detection

Signal

Reported information on a possible causal relationship between an adverse event and drug that was previously unknown or incompletely documented.

More than one report is needed to generate a signal, depending on:

- Quality of the information provided in the report
- Seriousness of the event reported



Who Should Report ADE?

All healthcare workers - doctors, nurses, pharmacists, dentists, etc. and patients

Regulation 40: Medicines and Related Substances Act, 1965 (Act 101 of 1965) as amended: A healthcare professional /provider, veterinarian or any other person should inform the Authority (SAHPRA), in the manner as determined by the Authority, of any suspected ADRs/AEFIs; or new or existing safety, quality or effectiveness concerns, occurring as a result of the use of any medicine or scheduled substance.

Profession	Role/Function
Nurse	 Initial contact for complaint and observation/description of suspected ADR Referral for evaluation and management of suspected ADR
Pharmacist	 Check and complete relevant medication history relative to the onset and duration of the suspected ADR Rational medicine use evaluation - identify any actual or potential medicine-related problems which may cause or contribute to ADRs
Medical officer and allied HCPs	 Evaluation of signs, symptoms or other abnormal clinical and laboratory findings Diagnosis of suspected ADR – differential diagnosis (disease vs disorder vs drug) Intervention and follow-up to resolve/prevent harm – severity of symptoms and seriousness of harm outcomes Check all relevant clinical information is provided when reporting suspected ADR

Pharmacy role in Pharmacovigilance and reporting ADE/ADR

		DOMA		SAFE AND RATIONAL US	SE OF MEDICINES AND M	IEDICAL						
	DOMAIN 2: SAFE AND RATIONAL USE OF MEDICINES AND MEDICAL DEVICES											
	COMPETENCIES				BEHAVIOURAL STATEMENTS							
	COMPETENCIES		Item no.	Entry Level into Practice	Intermediate Practice	Advanced Practice						
2.7	Pharmacovigilance		2.7.1	2.7.1.1 Monitor, receive, record and report quality defects, adverse drug reactions and events.	2.7.1.2 Manage pharmacovigilance activities and classify the events accordingly.	2.7.1.3 Design and implement interventions to prevent and minimise adverse drug events.						
			2.7.2	2.7.2.1 Perform post marketing surveillance studies.	2.7.2.2 Compile reports of the post marketing surveillance studies.	2.7.2.3 Review pharmacovigilance reports and report to regulatory authority.						
	66 No. 41621 GOVERNMENT GAZETTE, 11 MAY 2018											

✓ Right patient

✓ Right drug

✓ Right dose

✓ Right route

✓ Right time

National Drug Policy for South Africa

7.6 The role of pharmacists

Although all health care providers and the public are involved in the rational use of drugs, WHO has recommended a special role for pharmacists, particularly in quality assurance and in the safe and effective administration of drugs. Pharmacists will be in a strong position to promote the rational use of drugs through their extensive knowledge.

Detecting suspected ADEs/ADRs

- Listen carefully to client's complaints of symptoms suggestive of an ADR (subjective
- Check for any signs as objective evidence to suggest an ADR
 - New or unusual signs or symptoms
 - Abnormal laboratory test finding
 - Abnormality detected on imaging or diagnostics (CT scan, MRI, X-ray)
 - Abnormal clinical measurements (temperature, pulse, BP, blood glucose, body weight).
- Ask the client questions related to their treatment and how they feel
- Assess adherence (non-adherence may be due to intolerance to ADRs)
- Obtain a complete medication history
- Verify that the suspected medicine and other medicines were administered/taken prior to onset of the ADR
- Verify that the onset of the suspected ADE/ADR was after the medicine was administered/taken
- Consider whether the event is pharmacologically plausible

Detecting suspected ADRs

- Check for any medicine-related problems
 - Contraindications age, gender, weight, comorbidities, pregnancy, breastfeeding
 - Dosing is appropriate for indication, age, weight, renal/hepatic impairment
 - Drug interactions food, disease, other medicines (polypharmacy)
- Check if there have been any recent therapy adjustments dose changes, addition of therapy, discontinuation of therapy
- Check for any follow-up on outcomes of the suspected ADR following any interventions to resolve/prevent harm
- Consider alternative factors causing or contributing comorbidities, other medicines incl. OTC & CATM
- Check relevant up-to-date literature summary of product characteristic (SmPC), professional information (PI), guidelines, medical databases, journals

Not all ADRs may be adequately reflected in the SmPC/PI/PIL

Report What?

All adverse events with:

- All registered and unregistered medicines, including:
- Medical devices | In-vitro diagnostics
- Vaccines | Biologicals
- Complementary | Alternative | Traditional | Herbal | Natural products


Serious/severe events resulting in:

- Any intervention to resolve/prevent any harm
- Hospitalisation (initial/prolonged)
- Disability/impairment (temporary/permanent)
- Congenital anomaly/ birth defect
- Life-threatening
- Death


Significant events:

- In children, elderly, during pregnancy or breastfeeding
- Foetal or infant exposures during pregnancy/breastfeeding
- Newly marketed products (< 5 years)</p>
- Not clearly stated in package inserts
- Occurring more frequently than previously reported
- Resulting from interactions (drug, food, disease)
- Therapeutic failures

Should I report all ADEs?



Reporting to SAHPRA



Pharmacovigilance related queries: pvqueries@sahpra.org.za

ADR Reporting Form

Report adverse experiences with:

herbal remedies, etc).
Please report especially:

package insert.

suspected contamination,

poor packaging or labelling,

questionable stability.

defective components,

therapeutic failures.

SAHPRA

	ADVERSE DRUG REACTION (ADR)/ PRODUCT									SAHPRA					
	no. 6.04]		South African Health Products												
1010 000	. 110. 0.04j		ALITY PROB	Regulatory Authority											
Revisi	ion: 5.0	(PUB	LIC AND PRIVATE SEC	CTOR) (In	luding H	lerbal Proc	lucts)	Effective date: 21 August 2023							
	for CONSENT C Health Care Faci		rmation regarding re	eporting o	of PRODU	JCT QUALI	TY PROBLEM	1S and	ADVERSE	EVENTS F	OR VACCINE	S			
	, Loftus Park	inty/Fractice	E 111 / D 11												
402 Kirkne	ss Street, Arcad	ia,	Facility/Practice												
Pretoria Tel: (012) !	01 0211		District					Tel							
	r@sahpra.org.za		Province					Fax							
Patient De	tails														
Patient Initials		File/Reference	e Number					Date							
Sex	□M □F □Unk	Race		Wei	ght (kg)		Heigh	t (cm)	/Age	Pregnan	t?	□n □y			
Allergies		-		Esti	mated a	estational a	ige at time o	fread	tion		I				
-	ledicine(s) (Med	licines suspected	to have caused the				-			with the	suspect me	dicine(s)] O			
Interacting	[Other medicin		with the suspect me												
	products].	Medicine role		1		Date	1				1	-			
	e [Active Ingredient ame is unknown]	(Please tick the applicable box)	ick the Route		ng) and rval	Started/ Given	Date Stopp	ate Stopped		or use	Batch Number	Expiry Date			
		Suspect Concomita													
		□ Interacting													
		□ Suspect													
		Concomita													
		Suspect										-			
Concomita		Concomita													
											_				
		Suspect Concomita	nt												
	Interaction														
		Suspect													
		Concomita Interacting													
Adverse D	rug Reaction/Pro	oduct Quality Pro									1	_			
	ime of onset of r						action resol								
Please des	cribe Adverse Ev	ent/Product Qual	ity Problem: (kindly a	add as mu	ch clinic	al informat	ion as possi	ole)							
Interventio	on (Tick all that ap	(viq		Patient	Outcom	nes (Tick all	that apply)	4	DR seriou	sness crite	eria (Tick all t	hat apply)			
□ No interv	ention.			🗆 ADR	recovered	/resolved.		0	ADR seriousness criteria (Tick all that apply) Resulted in death.						
	tion unknown. ounselled/non-mee	dical traatment			vering/res	solving. /not resolve	d		Date of death: Patient hospitalised or hospitalisation prolonged.						
□ Discontin	ued suspect drug;	Replaced with:		C Reco	vered wit	h sequelae.		0	Life threatening.						
Decrease Treated #		age; New Dose:			resolved a		medicine wa	Impairment/disability. Congenital anomaly/ birth defect.							
Referred	to hospital: Hospit			ADR	reappeare	ed after resta	arting suspect			rtant conditio	n.				
□ Other int	ervention (e.g., dia		nilar drug Ione 🗆 Ur	(rechallenge sknown	e): □N □Y										
Laboratory	y Results					oratory Res	sults	- 1							
Lab Test		Test Result	Test Date	Lab Te	st			Т	est Result		Test	Date			
Co-morbid	lities/Other Mec	lical Condition(s)		1											
	,														
Reported I	by														
Name				E-mail											
Designatio		□Nurse □P	harmacist Doctor	□Othe											
Date repor	ted:						Signature								

THIS ADR REPORT IS NOT A CONFIRMATION THAT THE REPORTER OR THE SUSPECT MEDICINE(S) CAUSED THE ADR

ADVICE ABOUT VOLUNTARY REPORTING

Report even if:

- medications (medicines and biologicals),
 you're not certain the product caused the event,
- complementary / alternative medicines (including traditional,
 you don't have all the details.

Report Product Quality Problems via:

- phone: 0800 204 307
 - SAHPRA portal: <u>https://www.sahpra.org.za/complaints-</u> relating-to-medicine-and-medical-devices/

Report Adverse Events Following Immunisation (AEFI) experienced with vaccines on:

- the dedicated Case Reporting Form accessed from SAHPRA portal: <u>https://www.sahora.ore.za/healthproducts-vigilance/</u>
- forward the dedicated form to <u>AEFI@health.gov.za</u>
 phone: 0800 02 9999.
- phone coord of

Other reporting tools available at SAHPRA include: Med Safety Application

· adverse drug reactions to newly marketed products,

serious reactions and interactions with all products,
 adverse drug reactions which are not clearly reflected in the

Report Product Quality Problems such as:

The Med Safety Application is a mobile application designed for the public and healthcare professionals to report suspected ADRs/adverse event following immunisations (AEFIs). It is the preferred reporting tool by SAHPRA and allows for a seamless electronic submission of ADR/AEFI reports directly from the source into SAHPRA's reporting systems. The app can be downloaded onto a smart mobile phone directly from the SAHPRA website, <u>https://medsafety.sahpra.org.za</u>. For more reporting channels please visit SAHPRA website, <u>https://www.sahpra.org.za</u>

CONSENT CLAUSE

By the signature above, the reporter hereby provides consent to the processing of personal information provided for the purpose of reporting a suspected adverse reaction. The reporter acknowledges that this information may be used a) to access all medical and clinical records for the purpose of gathering additional information for a clinical meaningful data, when required; b) in the generation of statistics; and c) to make policy decisions relating to safe use of medicines.

SAHPRA Vigilance unit undertakes to collate the personal information contained in this form and collected during the process of reporting of suspected adverse drug reaction in a manner that adheres to the Protection of Personal Information Act, so that your personal data is processed fairly, lawfully and transparently, adequate, relevant, and limited to what is necessary, processed for specific and legitimate purpose, accurate and kept up to date where necessary, kept in an identifiable form no longer than necessary for the purpose, processed securely . SAHPRA has put appropriate technical and organisational measures to safeguard your information. The information will not be stored for any longer than is necessary to achieve the purpose for which it was collected, unless SAHPRA Vigilance unit has a lawful basis to do so. If the reporter wishes to access and/or rectify their personal information, they may do so by contacting SAHPRA Vigilance unit at 012 501 0311 or via email: <u>adr@sahpra.org.za</u>.

Confidentiality:

Identities of the reporter and patient will remain strictly confidential.

Your support of the South African Health Products Regulatory Authority's adverse drug reaction monitoring programme is much appreciated. Information supplied by you will contribute to the improvement of medicine safety and therapy in South Africa.

Doc Number:

CONSENT FORM | CASE REPORTING FORM (CRF) | CASE INVESTIGATION FORM (CIF)

Patient name & surname: EPID Number:	Mealth ALL VACCINES including COVID-19 CASE REPORTING FORM (CRF) FOR ADVERSE EVENTS FOLLOWING IMMUNISATION (AEFI)							MUNISATIC	health ALL VACCINES including COVID-19: CASE INVESTIGATION FORM (CIF) Adverse Events Following Immunisation (AEFI) AND Adverse Events of Special Interest (AESI)				
CONSENT CLAUSE FOR COLLECTION AND PROCESSING OF PERSONAL INFORMATION	EPID Number:	EPID Number: S O A - - - Date received Level Signature Country - Province District -							ONLY for Serious and Severe Adverse Events Following Immunisation, Clusters and Adverse Events of Special Inte				
By their signature below, the vaccine recipient or relative (in the event of the vaccine recipient bein unresponsive or has demised) or caregiver (in the case of a child) hereby provides consent to the collection	Today's date: D D / M / Y Y Y Y All fields in this form are mandatory, unless indicated 'if applicable', Provide					P	SECTION A: BASIC DETAILS Province:						
and processing of their personal information (as set out in this Case Reporting Form) by the Nationa Department of Health and third parties appointed by it (the "Department") for the purposes of investigatin	the requested information or tick the appropriate box. (Per oper service) SECTION A: IDENTIFYING INFORMATION NOTE: In maternal vaccination, if mother and baby / more than one baby are affected, complete separate form for each affected individual								NB: The EPID number must be IDENTICAL to the number on the CASE REPORTING FORM PATIENT IDENTIFICATION NOTE: In maternal vaccination, if mother and baby / more than one baby are affected, complete separate form for each affected individu				
and assessing potential adverse events related to a vaccine/s received. The vaccine recipient or relative (in	N Vaccine recipier	Vaccine recipient name & surname: Reporter's name & surname:								Vaccine recipient name & surname:			
the event of the vaccine recipient being unresponsive or has demised) or caregiver (in the case of a child acknowledges that this information may be used i) to access all medical and clinical records for the purpose	vaccine recipier	t's residential ad	ldress:				nation/Posi				Date of birth: DD / MM / YYY OR Age at onset: Years Months Days OR Age group: 0 - <1 year		
of case investigation, when required; ii) in the generation of statistics; and iii) to make policy decisions relating to vaccine safety and efficacy. This consent may be withdrawn at any time, and the vaccine recipient o			Telept	none no:		-					Patient's full residential address with landmarks (Street name, house number, locality, etc.):		
relative (in the event of the vaccine recipient being unresponsive or has demised) or caregiver (in the case o a child) may, at any time, object to the collection and processing of their personal information, by contactin				e: Pregnant	Breastfeed						Telephone no: E-mail: E-mail:E-mail:		
the Department (<u>AEFI@heath.gov.za</u>) and the South African Health Products Regulatory Authorit (<u>adr@sahpra.org.za</u>).	y OR Age at onset OR Age group:					Date p		ified event t	o health	system:	Name & surname of reporting officer:		
The Department undertakes to process the personal information contained in this Case Reporting Form, and	If applicable: Gestation: Full-term Premature										Date of filling this form: DD/MM/YYYY Date of investigation: DD/MM/YYYY This report is: First Interim Final		
collected during the process of case investigation in a manner that adheres to the Protection of Persona Information Act. The information will not be stored (in a manner that identifies the vaccine recipient) for an	y N	ON B: VACCINE	of a foeta	l adverse event	t, ALSO record	the mother's	s maternal	vaccination	details		Date of onset of event: DD/MM/YYYY Time of first symptom: Hr Min Date first reported to the health authority: DD/MM/YYYY Date of hospitalization (if applicable): DD/MM/YYYY Status on the date of investigation: Died Disabled Reco		
longer than is necessary to achieve the purpose for which the information was collected, unless the Department has a lawful basis to do so. If the vaccine recipient or relative (in the event of the vaccine	Address / locati	Address / location: Recovered completely Recovered with complications Unknown								Recovered completely Recovered with complications Unknown			
recipient being unresponsive or has demised) or caregiver (in the case of a child) wishes to access and/o rectify their personal information, they may do so by contacting the Department (<u>AEFI@heath.gov.za</u>).	r Vaccine/s given (Use trade name)		ime D	Rose Batch/ Lot number number		VVM Stage ((if applies)	Manufacturer	Batch/ Lot number		Date & time of reconstitution	If died, date of death: DD/MM/YYYY Time of death: Hr Min Autopsy done: Yes No If YES, date of autopsy: DD/MM/YYYY Attach report (if available) If NO, autopsy planned: Date: DD/MM/YYYY Time Hr Min Autopsy NOT done nor planned. Provide reasons:		
Vaccine recipient: (Name and Surname)											IMMUNISATION HISTORY		
Signed by the vaccine recipient / relative / caregiver*	Consumables	Needles	Si	ze:	Batch:		Expir	y date:			Name of vaccinator: Name of vaccination site:		
	pre-filled)	used (unless pre-filled) Syringes Size:Batch:Expiry date: SECTION C: TRIGGER EVENTS								-	Place of vacination intermined in the intermined in the intermined intermined in the intermined inter		
Name and Surname Signature Date	Date & time AEFI started: DD/MM/YYYY Hr Min Adverse event (s): (Tick (*) all boxes that apply) Minor local reactions Minor systemic reactions							;): (Tick (√)	s that apply)	TRIGGER EVENTS			
*Delete what is not applicable	Minor local reactions Minor systemic reactions Swelling <scm< td=""> Induration / hardness Excessive crying (infant) Mild fever <38°C</scm<>							nent, [dy aches	Minor local reactions Minor systemic reactions Swelling <scm< td=""> Induration / hardness Excessive crying (infant) Mild fever <38°C</scm<>			
ALL VACCINES including COVID-19: AEFI CRF Page 3/3 Case Report Form_AEFI_All vaccines ind COVID-19_20211221	- ALL VACCINES i	ncluding COVI)_19· ΔFF	I CRF Page 1/2		Case Report Fo	wm AFFI All	vacions ind (0/10-19 2	0211221	ALL VACCINES including COVID-19: AEFI & AESI CIF Page 1/6 duster AESI All vaccines 20210128 Case Investigation Form_AEFI serious, se		

SAHPRA's response to safety concerns



Changes to product labelling which can be addition of warnings, precautions or adverse effect in the Professional Information and Patient Information Leaflet.



Distribute Dear Healthcare Professional Letters (DHCPL) or publish medicine safety alerts (MSA) in medical journals to inform healthcare professionals.



Issue press releases to inform consumers.



Limit/restrict access to the health product by either up-scheduling, limiting prescribing indication and population, etc.



Recall, suspend or cancel the registration of a product.



Undertake post-marketing studies to investigate the safety concern if more information is needed.

PREVENTION

UNDERSTANDING

Inform + Prevent

Guidelines Policies & Protocols Restriction Medicine alerts/ recalls Withdrawal/suspension Media statements Training & education



REGULATOR & POLICY MAKERS

Estimate + Understand


Further studies Seriousness and severity Trends, risk factors Incidence and prevalence

Review + Update

Rescheduling/restrictions Labelling/packaging PIL, PI updates



PHARMACOVIGILANCE CYCLE



PHARMACOVIGILANCE CENTRE

Collect + Assess + Research

Causality & Preventability Signal detection, trends, risk factors

Train + Educate
Pharmacovigilance & ADE reporting






PHARMACEUTICAL Collect + Research Pre- & post-marketing safety information

ASSESSMENT

DETECTION

SAHPRA Health Products Vigilance Portal: www.sahpra.org.za/health-products-vigilance



Reporting Tools

F

0

R

Μ

S

0

Ν

Ν

E

Reporting Form ADR | PQC Submit by e-mail: adr@sahpra.org



ADR | PQC

http://primaryreporting.who-umc.org/ZA

Link to Guidelines ADR - adverse drug reaction; AEFI - adverse event following immunisation



Case Reporting Form

AEFI (all)

Case Reporting Form AESI incl COVID-19

PQC - product quality concerns



Case Investigation Form Serious or severe AEFI + AESI

Submit by e-mail: AEFI@health.gov.za + District EPI Surveillance officer





THANK YOU